EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial

Daniel H Ahn iD, Maya Ridinger iD, Timothy L Cannon iD, Lawrence Mendelsohn, Jason S Starr iD, Joleen M Hubbard iD, Anup Kasi iD, Afsaneh Barzi iD, Errin Samuëlsz iD, Anju Karki iD, Ramanand A Subramanian iD, Divora Yemane und 6 weitere

Journal of Clinical Oncology · 2025-03 · 43 (7) · 840-851

DOI: 10.1200/jco-24-01266 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025-03. Verfasst von Daniel H Ahn und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Mayo Clinic, Phoenix, AZ. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE This phase II study evaluated the efficacy and tolerability of onvansertib, a polo-like kinase 1 (PLK1) inhibitor, in combination with fluorouracil, leucovorin, and irinotecan (FOLFIRI) + bevacizumab for the second-line treatment of KRAS -mutant metastatic colorectal cancer (mCRC). PATIENTS AND METHODS This multicenter, open-label, single-arm study enrolled patients with KRAS -mutated mCRC previously treated with oxaliplatin and fluorouracil with or without bevacizumab. Patients received onvansertib (15 mg/m 2 once daily on days 1-5 and 15-19 of a 28-day cycle) and FOLFIRI + bevacizumab (days 1 and 15). The primary end point was the objective response rate (ORR), and secondary endpoints included progression-free survival (PFS), duration of response (DOR), and tolerability. Translational and preclinical studies were conducted in KRAS -mutant CRC. RESULTS Among the 53 patients treated, the confirmed ORR was 26.4% (95% CI, 15.3 to 40.3). The median DOR was 11.7 months (95% CI, 9.4 to not reached). Grade 3/4 adverse events were reported in 62% of patients. A post hoc analysis revealed that patients with no prior bevacizumab treatment had a significantly higher ORR and longer PFS compared with patients with prior bevacizumab treatment: ORR of 76.9% versus 10.0% (odds ratio of 30.0, P < .001) and median PFS of 14.9 months versus 6.6 months (hazard ratio of 0.16, P < .001). Our translational findings support that prior bevacizumab exposure contributes to onvansertib resistance. Preclinically, we showed that onvansertib inhibited the hypoxia pathway and exhibited robust antitumor activity in combination with bevacizumab through the inhibition of angiogenesis. CONCLUSION Onvansertib in combination with FOLFIRI + bevacizumab showed significant activity in the second-line treatment of patients with KRAS -mutant mCRC, particularly in patients with no prior bevacizumab treatment. These findings led to the evaluation of the combination in the first-line setting (ClinicalTrails.gov identifier: NCT06106308 ).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsProto-Oncogene Proteins p21(ras)HumansBevacizumabMaleFemaleMiddle AgedAgedAdultMutationLeucovorinFluorouracilCamptothecinProgression-Free SurvivalAged, 80 and over

Substanzen

BevacizumabProto-Oncogene Proteins p21(ras)KRAS protein, humanLeucovorinFluorouracilCamptothecin

Autor:innen und Institutionen

  • Division of Medical Oncology, Mayo Clinic, Phoenix, AZ.
  • Cardiff Oncology Inc, San Diego, CA.
  • Inova Schar Cancer Institute, Fairfax, VA.
  • Carti Cancer Center, Little Rock, AR.
  • Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL.
  • Division of Oncology, Department of Medicine, Mayo Clinic, Rochester, MN.

ORCID-Profile: Daniel H Ahn, Maya Ridinger, Timothy L Cannon, Jason S Starr, Joleen M Hubbard, Anup Kasi, Afsaneh Barzi, Errin Samuëlsz, Anju Karki, Ramanand A Subramanian, Chu-Chiao Wu, Peter J P Croucher, Heinz-Josef Lenz

Zitieren

APA

Ahn, D. H., Ridinger, M., Cannon, T. L., Mendelsohn, L., Starr, J. S., Hubbard, J. M., Kasi, A., Barzi, A., Samuëlsz, E., Karki, A., Subramanian, R. A., Yemane, D., Kim, R., Wu, C. C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H. J. (2025). Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. Journal of Clinical Oncology, 43(7), 840-851. https://doi.org/10.1200/jco-24-01266

Vancouver

Ahn DH, Ridinger M, Cannon TL, Mendelsohn L, Starr JS, Hubbard JM, et al. Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. Journal of Clinical Oncology. 2025;43(7):840-851. doi:10.1200/jco-24-01266

BibTeX
@article{Ahn2025,
  author = {Ahn, Daniel H and Ridinger, Maya and Cannon, Timothy L and Mendelsohn, Lawrence and Starr, Jason S and Hubbard, Joleen M and Kasi, Anup and Barzi, Afsaneh and Samuëlsz, Errin and Karki, Anju and Subramanian, Ramanand A and Yemane, Divora and Kim, Roy and Wu, Chu-Chiao and Croucher, Peter J P and Smeal, Tod and Kabbinavar, Fairooz F and Lenz, Heinz-Josef},
  title = {Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {7},
  pages = {840--851},
  doi = {10.1200/jco-24-01266}
}
Kostenlos starten →